Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future

被引:8
|
作者
Wang, Lun [1 ,2 ]
Zhang, Yang
Zhang, Shu-Yang [1 ,2 ]
机构
[1] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Cardiol, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
关键词
Cardiovascular disease; Coronary artery disease; Rheumatoid arthritis; C-REACTIVE PROTEIN; KILLER T-CELLS; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; NECROSIS-FACTOR INHIBITORS; INSULIN-RESISTANCE; LIPID PROFILE; HEART-DISEASE; TNF-ALPHA; INTERLEUKIN-6; INHIBITION; ENDOTHELIAL DYSFUNCTION;
D O I
10.1097/CM9.0000000000000530
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen. Data sources: This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations, including coronary artery disease, myocardial ischemia, cardiovascular diseases, RA, rheumatic diseases, treatment, therapy, strategies, immunotherapy, inflammation, and anti-inflammation. Study selection: All retrieved literature was scrutinized, most relevant articles about the pathogenic mechanism and clinical management, especially anti-inflammatory therapy of RA-associated CAD were reviewed. Results: RA is an immune-mediated chronic inflammatory disease which has a great social disease burden. In addition to typical arthritic manifestations, RA also affects extra-articular tissues and organs, within which the involvement of the cardiovascular system, especially incorporating CAD, is the leading cause of death for patients with RA. Recently, numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA. The effect of traditional RA drugs on CAD risk management has been gradually clarified, and more emerging biologic agents are being explored and studied, which have also achieved satisfactory outcomes. Furthermore, with the success of the CANTOS clinical trial, novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect. Conclusions: RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population.
引用
收藏
页码:2972 / 2983
页数:12
相关论文
共 50 条
  • [1] Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
    Wang Lun
    Zhang Yang
    Zhang Shu-Yang
    [J]. 中华医学杂志(英文版), 2019, 132 (24) : 2972 - 2983
  • [2] Rheumatoid arthritis-associated lung disease
    Shaw, Megan
    Collins, Bridget F.
    Ho, Lawrence A.
    Raghu, Ganesh
    [J]. EUROPEAN RESPIRATORY REVIEW, 2015, 24 (135): : 1 - 16
  • [3] Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Ibraheim, Marina Kristy
    Govindu, Rukma Reddy
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2020, 359 (05): : 312 - 313
  • [4] Rheumatoid arthritis-associated interstitial lung disease
    Abdulaziz, Sultana
    [J]. CURRENT PULMONOLOGY REPORTS, 2015, 4 (03) : 135 - 141
  • [5] Rheumatoid arthritis-associated interstitial lung disease
    Sharma, S.
    Minhas, R.
    Shankar, S.
    Taha, O.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2019, 112 (10) : 815 - 816
  • [6] Rheumatoid arthritis-associated interstitial lung disease
    Sultana Abdulaziz
    [J]. Current Pulmonology Reports, 2015, 4 (3) : 135 - 141
  • [7] Rheumatoid arthritis-associated interstitial lung disease
    Solomon, Joshua J.
    Brown, Kevin K.
    [J]. OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2012, 4 : 21 - 31
  • [8] RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE WITHOUT ARTHRITIS
    Matayeva, Elyana
    Henson, Theresa
    Iqbal, Javed
    Alaverdian, Artur
    [J]. CHEST, 2018, 154 (04) : 408A - 408A
  • [9] RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE WITHOUT CLINCAL ARTHRITIS?
    Bagley, A.
    Demoruelle, K.
    Schwarz, M.
    Cool, C.
    Deane, K.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (01) : 193 - 193
  • [10] Biomarkers of Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Chen, Juan
    Doyle, Tracy J.
    Liu, Yongliang
    Aggarwal, Rohit
    Wang, Xiaoping
    Shi, Yonghong
    Ge, Sheng Xiang
    Huang, Heqing
    Lin, Qingyan
    Liu, Wen
    Cai, Yongjin
    Koontz, Diane
    Fuhrman, Carl R.
    Golzarri, Maria F.
    Liu, Yushi
    Hatabu, Hiroto
    Nishino, Mizuki
    Araki, Tetsuro
    Dellaripa, Paul F.
    Oddis, Chester V.
    Rosas, Ivan O.
    Ascherman, Dana P.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67 (01) : 28 - 38